The first malaria vaccine in Kenya: the view from health professionals, community leaders and parents
Nearly 4 years after the introduction of the RTS,S/AS01 (or RTS,S) malaria vaccine in parts of Kenya, the WHO Malaria Vaccine Implementation Programme (MVIP) team visited government offices, health facilities and homes in the country’s western region to hear from health professionals, community members and caregivers about what the malaria vaccine means to them and how the 4-dose vaccine is being integrated into the national immunization programme.
The feedback received was extremely positive. More than 4.5 million doses have been provided through the countries’ Expanded Programmes on Immunization during the pilot introductions in Ghana, Kenya and Malawi. The vaccine has been shown to be safe and effective, reducing life-threatening severe malaria and child deaths. The high community demand for the vaccine may present opportunities to bring children back to clinics to catch up on any missed vaccines or child health services.
The first malaria vaccine was recommended for use to prevent malaria in children in October 2021. More than 1.4 million children have received the vaccine across the 3 pilot countries since 2019, of which, 400 000 children in Kenya have received at least their first dose. If implemented broadly, the vaccine could save tens of thousands of lives each year.
But what does this mean in practice and day-to-day life? Here is what we saw and heard in Kenya.
Related
News
Fact sheets
Events